NCT04943757View on ClinicalTrials.gov

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Myeloid Leukemia, AcuteChronic Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm
Interventions
DRUG

Bendamustine Hydrochloride

50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation

DRUG

Cyclophosphamid

25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation

Trial Locations (1)

197022

RM Gorbacheva Research Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT04943757 - Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies | Biotech Hunter | Biotech Hunter